Symptom-Onset Treatment for Women with Premenstrual Dysphoric Disorder

Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA.
Journal of Clinical Psychopharmacology (Impact Factor: 3.24). 05/2006; 26(2):198-202. DOI: 10.1097/
Source: PubMed


Symptoms of premenstrual dysphoric disorder (PMDD) respond to serotonin reuptake inhibitors when treatment is limited to 14 days of the menstrual cycle. Many women have less than a week of symptoms, and shorter treatment intervals would further reduce medication exposure and costs.
Twenty women with PMDD were randomly assigned to either paroxetine CR or placebo for 1 cycle and crossed over to the other condition for a second cycle. Subjects initiated treatment when premenstrual symptoms began and stopped within 3 days of beginning menses.
Women took capsules for an average of 9 days (range, 3-15 days), including the first few days of menses. Moderate "PMDD level" symptoms occurred in 1 subject (6%) for 2 days and 4 subjects (24%) for 1 day before starting paroxetine or placebo. Daily Record of Severity of Problems scores were lower in the paroxetine group compared with the placebo group, although the differences were not statistically significant. However, the mean on-treatment Inventory of Depressive Symptomatology (clinician-rated) score for the paroxetine group was 17.9 +/- 8.3 compared with 31.5 +/- 11.2 in the placebo group (adjusted mean difference = 13.6, P = 0.009). Response (Clinical Global Impressions Scale score of 1 or 2) occurred in 70% of subjects randomized to paroxetine CR and 10% of those assigned to placebo (chi2(1) = 7.5, P = 0.006). Discontinuation symptoms did not differ in the groups.
These data suggest the need to further evaluate symptom-onset treatment in a larger randomized clinical trial.

Download full-text


Available from: Kimberly Ann Yonkers, Nov 11, 2014
10 Reads
  • Source
    • "Women with PMDD are also more likely to report physical symptoms such as bloating and breast tenderness (Di Giulio and Reissing, 2006; Hartlage et al., 2012) and irritability (Angst et al., 2001; Landen and Eriksson, 2003) as opposed to depressed mood (Bhatia and Bhatia, 2002). Additionally, treatment response to medications differs as women with PMDD report alleviation of symptoms almost immediately after administration of the serotonin reuptake inhibitors (SRIs; Steiner et al., 2005, 2008; Yonkers et al., 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Premenstrual dysphoric disorder (PMDD) is a chronic condition that significantly affects a woman's well-being on a monthly basis. Although co-occurrence of PMDD and major depressive disorder (MDD) is common, most studies examine whether women with PMDD are at risk for depression and investigations of PMDD in depressed women are scant. Therefore, the present study examined rates of PMDD in young depressed women. PMDD was assessed using a structured clinical interview (SCID-PMDD) in a sample of 164 young women with (n=85) and without (n=79) any history of depression. Rates of PMDD were elevated among women with MDD in this sample. This result held true regardless of participants' MDD status (current, lifetime or past history-only symptoms of MDD) and regardless of whether all or most DSM-IV-TR PMDD criteria were met. Sample size in the present study was relatively small, and daily diary data were not available to confirm a PMDD diagnosis. The current study highlights the need for clinicians to assess for PMDD in young female patients with major depression. Depressed women experiencing the added physical and psychological burden of PMDD may have a more severe disease course, and future studies will need to identify appropriate treatments for this subset of depressed women.
    Journal of Affective Disorders 06/2013; 150(3). DOI:10.1016/j.jad.2013.05.091 · 3.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The results of investigation of possible figure of merit increase of thermoelectric materials through the use of superlattices are given. It has been established that phonon thermal conductivity has a considerable effect on the figure of merit of such thermoelectric materials. It has been discovered that additional periodicity caused by the superlattice structure results in phonon spectrum transformation which affects κ<sub>ph</sub>. By example of Si<sub>n</sub>/Ge<sub>m</sub> superlattices the vibration spectrum has been calculated for various number of superlattice layers. It has been also established that thermal conductivity of such systems is decreased as compared to bulk thermal conductivity of Si and Ge. At the same time α and σ increase with reduction of the number of superlattice layers m which indicates the possibility of considerable thermoelectric figure of merit growth for short-period superlattices
    Thermoelectrics, 1998. Proceedings ICT 98. XVII International Conference on; 06/1998
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A lattice determination of the form factor and decay constants for the semileptonic decay of heavy pseudoscalar (PS) mesons at zero recoil is presented from which the soft pion relation is satisfied. Chiral extrapolation of the form factor is performed at constant $q^2$. Pole dominance is used to extrapolate the form factor in heavy quark mass. At the B mass, the form factor at zero recoil lies somewhat below the ratio of decay constants; the relation remains satisfied within error.
    Nuclear Physics B - Proceedings Supplements 11/1999; 83-84. DOI:10.1016/S0920-5632(00)91658-X · 0.88 Impact Factor
Show more